Shattuck Labs, Inc.
(NASDAQ : STTK)

( )
STTK After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.16%285.941.5%$893.22m
MRNAModerna, Inc. 3.17%181.480.0%$781.65m
GILDGilead Sciences, Inc. 0.08%87.901.0%$714.72m
REGNRegeneron Pharmaceuticals, Inc. 1.27%761.242.6%$526.50m
VRTXVertex Pharmaceuticals, Inc. 1.38%320.761.9%$498.80m
BIIBBiogen, Inc. -1.09%301.851.8%$409.62m
ILMNIllumina, Inc. 1.28%220.863.2%$264.16m
BNTXBioNTech SE 1.47%169.470.0%$176.40m
BMRNBioMarin Pharmaceutical, Inc. 2.02%103.024.2%$165.66m
SNSSSunesis Pharmaceuticals, Inc. -3.02%2.250.7%$157.28m
AXSMAxsome Therapeutics, Inc. -0.44%71.971.6%$142.81m
MRTXMirati Therapeutics, Inc. 0.13%91.501.6%$136.39m
NVAXNovavax, Inc. 2.18%16.8575.3%$77.01m
HALOHalozyme Therapeutics, Inc. 0.24%57.4018.4%$76.37m
TXG10X Genomics, Inc. 2.35%39.570.0%$58.25m

Company Profile

Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. It primarily focuses on Agonist Redirected Checkpoint (ARC) and Gamma Delta T Cell Engagers (GADLEN) platforms. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.